Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Instagram Outage Disrupts Thousands of U.S. Users 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SAN DIEGO, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Evofem, Inc. announces that Sandra Matsumoto has been named Vice President of Global Regulatory Affairs effective immediately. In this role, Dr. Matsumoto will be responsible for global regulatory strategy and lifecycle management of the Evofem product portfolio. She will report to Evofem Senior Vice President of Regulatory Affairs and Quality Assurance, Mary Jarosz.
"Sandra has extensive experience in the biotech and pharmaceutical industry," said Jarosz. "She has implemented global strategies from development to commercialization across several therapeutic areas and is a great addition to a well-established regulatory team."
Prior to joining Evofem, Dr. Matsumoto was the Senior Director of Global Regulatory Affairs for Vital Therapeutics, Inc., where she led biologics license application preparation for the treatment of severe liver disease. Before joining Vital, she held positions with increasing levels of responsibility in the areas of regulatory affairs, clinical development, and discovery research with several companies including Shire Regenerative Medicine and Illumina.
Dr. Matsumoto earned her PhD in Pharmacology and Toxicology from the University of Utah, her Master's of Science in Biology from California State University, Northridge and her Bachelor's of Science in Biology from UCLA. She also holds RAC certifications for the U.S. and E.U.
About Evofem
Evofem, Inc. is a late stage biotechnology company, headquartered in San Diego, CA, which focuses on the development and commercialization of women's reproductive health products, with a core focus on contraception.
Evofem, Inc. seeks to address a growing global contraceptive market, while delivering effective, woman-controlled products with global distribution. Evofem has two lead product candidates; Amphora, a non-hormonal contraceptive gel, and the Nestorone Ring, a one-year contraceptive vaginal ring, both of which have completed Phase III clinical studies.
For further information on the Company, please visit: www.evofem.com
CONTACT: Media Inquiries
Ellen Thomas
+1.718.490.3248
[email protected]
